Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.

ABSTRACT:

Importance

As the third most frequently mutated gene in cancers, the association between MUC16 mutation and response to immune checkpoint inhibitors (ICIs) in solid tumors remains unclear.

Objective

To examine whether MUC16 mutation is associated with genomic factors in ICI response in solid tumors and with outcomes in ICI-treated patients.

Design, setting, and participants

This cohort study used multidimensional genomic data of 10 195 patients from The Cancer Genome Atlas (TCGA) across 30 solid tumor types, 56 patients from a non-small cell lung cancer (NSCLC) cohort, and 145 patients from a melanoma cohort. Genomic factors associated with ICI response covered tumor mutational burden, neoantigens, immune-related gene signatures, and tumor immune microenvironment. Bot

SUBMITTER: Zhang L 

PROVIDER: S-EPMC7450349 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature